- Home
- PULM vs BLRX Comparison
PULM vs BLRX Comparison
Compare PULM & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- BLRX
- Stock Information
- Founded
- PULM 2003
- BLRX 2003
- Country
- PULM United States
- BLRX Israel
- Employees
- PULM N/A
- BLRX N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- BLRX Health Care
- Exchange
- PULM Nasdaq
- BLRX Nasdaq
- Market Cap
- PULM 20.5M
- BLRX 17.0M
- IPO Year
- PULM N/A
- BLRX 2011
- Fundamental
- Price
- PULM $4.71
- BLRX $3.71
- Analyst Decision
- PULM
- BLRX Strong Buy
- Analyst Count
- PULM 0
- BLRX 2
- Target Price
- PULM N/A
- BLRX $19.00
- AVG Volume (30 Days)
- PULM 10.4K
- BLRX 40.4K
- Earning Date
- PULM 08-06-2025
- BLRX 08-14-2025
- Dividend Yield
- PULM N/A
- BLRX N/A
- EPS Growth
- PULM N/A
- BLRX N/A
- EPS
- PULM N/A
- BLRX N/A
- Revenue
- PULM $369,000.00
- BLRX $17,251,000.00
- Revenue This Year
- PULM N/A
- BLRX N/A
- Revenue Next Year
- PULM $134.88
- BLRX N/A
- P/E Ratio
- PULM N/A
- BLRX N/A
- Revenue Growth
- PULM N/A
- BLRX 1.19
- 52 Week Low
- PULM $1.78
- BLRX $2.30
- 52 Week High
- PULM $10.40
- BLRX $32.26
- Technical
- Relative Strength Index (RSI)
- PULM 32.51
- BLRX 39.17
- Support Level
- PULM $4.65
- BLRX $3.58
- Resistance Level
- PULM $5.09
- BLRX $4.17
- Average True Range (ATR)
- PULM 0.28
- BLRX 0.27
- MACD
- PULM -0.01
- BLRX -0.01
- Stochastic Oscillator
- PULM 5.38
- BLRX 37.11
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.